Can a diabetes drug help hearts heal better after a heart attack?

NCT ID NCT07469943

First seen Mar 18, 2026 · Last updated Jun 22, 2026 · Updated 11 times

Summary

This study looks at whether empagliflozin, a medicine used for diabetes, can help blood vessels and heart muscle recover after a heart attack. About 80 people who had a severe heart attack will either receive empagliflozin or standard care. Researchers will measure artery stiffness, blood vessel health, and heart function over 12 months to see if the drug makes a difference.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Attikon University Hospital, 2nd Department of Cardiology, National and Kapodistrina University of Athens

    RECRUITING

    Athens, Rimini1/Haidari, 12462, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

empagliflozin (a diabetes pill that also helps the heart)

What this could lead to

If it works, this could show that empagliflozin helps blood vessels and the heart recover better after a heart attack, potentially reducing future heart problems.

What could go wrong

This is a small, early-stage study with only 80 people, so results may not apply to everyone. It is not designed to prove that empagliflozin prevents death or major events.

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.